The Genetically Engineered Mouse Facility (GEMF) generates mouse models for MD Anderson Cancer Center members and offers essential services for archiving important models and receiving novel models from outside sources. The facility provides gene-targeting in mouse embryonic stem cells, blastocyst injection services, pronuclear injection services, embryo and sperm cryopreservation services, rederivation services, in vitro fertilization (IVF), generation of novel mouse embryonic stem cells, and various resources for generating DNA constructs and generating and testing conditional GE mice. In the past 5 years, over 1,200 animal lines were generated by either pronuclear injection or blastocyst injection;over 200 clones were generated by gene-targeting;more than 15,000 embryos were frozen;more than 3,500 straws of sperm were archived, and more than 200 mouse lines were cleaned through rederivation. In addition to knockout mice, the facility has made mouse strains with unique fusions, mutations or protein isoforms to further elucidate genetic effects. Utilization of GEMF services has remained steady at 200-300 procedures per year between 2007 and 2011. The GEMF has seen increases in services such as rederivation, used as more models are brought into the institution, and the mouse archiving services of embryo and sperm cryopreservation. The GEMF has provided services to members of 18 CCSG programs during the last 5 years, serving over 100 Cancer Center members. Peer-reviewed investigators account for 89% of the utilization and 51% of total costs are requested from the CCSG. Publications cited using the GEMF have appeared in Nature, Science, Cell Stem Cell, PNAS and Nat Med. Institutional support for the facility includes over $120,000 in funding for capital equipment since 2007. Future plans include working with the newly established Tai Effector Nucleases facility that can be used to quickly generate targeted animal models. The GEMF is exploring cryopreservation protocols that are more effective at producing high percentage IVF-capable sperm, and the use of IVF to quickly and efficiently produce large numbers of embryos.

Public Health Relevance

Genetically engineered animal models are essential to study various pathological conditions and the manner in which they impinge upon cancer development and progression. This core provides unique models with wide application to basic and translational research. The GEMF supplies indispensible expertise to generate these models in an efficient and cost-effective manner using state-of-the-art procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759771
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$474,690
Indirect Cost
$178,134
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Dang, Nam H; Ogura, Michinori; Castaigne, Sylvie et al. (2018) Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182:583-586
Chahoud, Jad; Sui, Dawen; Erwin, William D et al. (2018) Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24:2304-2311
Andermann, Tessa M; Peled, Jonathan U; Ho, Christine et al. (2018) The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant 24:1322-1340
Tiwary, Shweta; Morales, John E; Kwiatkowski, Sam C et al. (2018) Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a. Sci Rep 8:8267
Chen, Han; Li, Chunyan; Peng, Xinxin et al. (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173:386-399.e12
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 12418 publications